Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of relapsing-remitting multiple sclerosis (RRMS). Understanding the impact of different disease modifying therapies on the CSF biomarker profile may increase their implementation in clinical practice and their appropriateness for monitoring treatment efficacy. This study investigated the influence of first-line (interferon beta) and second-line (natalizumab) therapies on seven CSF biomarkers in RRMS and their correlation with clinical and radiological outcomes. We included 59 RRMS patients and 39 healthy controls. The concentrations of C-X-C motif chemokine 13 (CXCL13), C-C motif chemokine ligand 2 (CCL2), chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein, neurofilament light protein (NFL), and neurogranin were determined by ELISA, and chitotriosidase (CHIT1) was analyzed by spectrofluorometry. RRMS patients had higher levels of NFL, CXCL13, CHI3L1, and CHIT1 than controls (p < 0.001). Subgroup analysis revealed higher NFL, CXCL13 and CHIT1 levels in patients treated with first-line therapy compared to second-line therapy (p = 0.008, p = 0.001 and p = 0.026, respectively). NFL and CHIT1 levels correlated with relapse status, and NFL and CXCL13 levels correlated with the formation of new magnetic resonance imaging lesions. Furthermore, we found an association between inflammatory and degenerative biomarkers. The results indicate that CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 correlate with the clinical and/or radiological disease activity, providing additional dimensions in the assessment of treatment efficacy.
reflect disease activity, and CSF levels decrease toward normality during intervention with disease modifying therapies (DMTs) (Lycke et al. 1998; Franciotta et al. 2001; Sellebjerg et al. 2009; Comabella et al. 2010; Conductier et al. 2010; Verbeek et al. 2010; Axelsson et al. 2011 Axelsson et al. , 2014 Gunnarsson et al. 2011; Khademi et al. 2011; Olsson et al. 2012; Malmestrom et al. 2014; Kuhle et al. 2015a) . Previous investigations of CSF biomarkers revealed altered immune cell (Sospedra and Martin 2005) and protein profiles, reflecting different aspects of the immunopathogenesis of MS (Malmestrom et al. 2003; Sellebjerg et al. 2009; Axelsson et al. 2011) .
Neurofilament light protein (NFL) is a major component of the cytoskeleton of the axon, and elevated levels of NFL in the CSF of MS patients indicate ongoing neuro-axonal degeneration (Lycke et al. 1998; Malmestrom et al. 2003) . NFL levels are increased in the CSF during all stages of MS, with the highest levels following acute relapses (Malmestrom et al. 2003) or during contrast enhancement of lesions on magnetic resonance imaging (MRI) . DMTs reduce the CSF levels of NFL (Gunnarsson et al. 2011; Axelsson et al. 2014; Kuhle et al. 2015a) .
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-40) is expressed by microglia, macrophages, epithelial cells, and astrocytes and is involved in the pathogenesis of chronic autoimmune disorders (Bonneh-Barkay et al. 2012) . High CSF levels of CHI3L1 have been associated with disability progression and, together with NFL, are higher in patients with shorter time conversion to MS from a clinically isolated syndrome (CIS) (Comabella et al. 2010; Martinez et al. 2015) . CSF CHI3L1 levels are reduced by DMTs . Glial fibrillary acidic protein (GFAP) is also expressed by astrocytes. The concentration of GFAP in the CSF is thought to reflect astrogliosis, and increased concentrations of GFAP and CHI3L1 have been associated with the progression of disability in MS (Malmestrom et al. 2003; Axelsson et al. 2011) (Martinez et al. 2015) .
Chitotriosidase (also known as chitinase 1, CHIT1) is a marker of microglial activation (Verbeek et al. 2010; Olsson et al. 2012) . Elevated CHIT1 levels are associated with conversion to MS in patients with CIS (Mollgaard et al. 2016) . Treatment with natalizumab reduces CHIT1 levels (Olsson et al. 2012) .
C-X-C motif chemokine 13 (CXCL13) is a B-cell chemokine. The concentration of CXCL13 in CSF is increased in patients with active MS and in patients converting from CIS to MS (Khademi et al. 2011) . CXCL13 levels are reduced by natalizumab treatment (Sellebjerg et al. 2009 ).
C-C motif chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, is an important chemokine for the recruitment of monocytes and macrophages to the CNS. The CNS levels of CCL2 are reduced during increased disease activity in MS (Franciotta et al. 2001; Mahad and Ransohoff 2003) .
Neurogranin (NGRN) is a postsynaptic protein enriched in dendritic spines. Elevated levels of NRGN have been found in subjects with mild cognitive impairment (MCI) and Alzheimer's disease (AD) (Thorsell et al. 2010; Kester et al. 2015) . In CSF, NGRN is a marker of synaptic integrity and its levels are influenced by neurodegeneration (Portelius et al. 2015) .
In this study, we explored the possible relationships between these CSF biomarkers of inflammation and degeneration in RRMS compared to healthy controls, as well as the influence of different DMTs on biomarker levels. A better understanding of the relationships between these biomarkers could lead to their implementation in clinical practice and treatment monitoring.
Material and methods

Patients and healthy controls
Patients with RRMS fulfilling the revised McDonald criteria (Polman et al. 2011) who had an indication to switch therapies because of breakthrough disease activity (n = 40), tolerability/ adverse events (n = 2), or risk of progressive multifocal leukoencephalopathy because of John Cunningham virus antibody positivity during natalizumab therapy (n = 17) were consecutively enrolled in the study at the MS centers of Sahlgrenska University Hospital, Gothenburg (n = 17), and Karolinska University Hospital, Stockholm, Sweden (n = 42). A total of 59 patients were enrolled, 7 were treatment na€ ıve (n = 4), or without DMT for 1 year or more, 33 were on first-line (interferon beta) and 19 were on second-line treatment (natalizumab) for at least 1 year before the study.
Thirty-nine blood donors and university students served as healthy controls. None of the controls had any neurological signs or a history of neurological disease. The demographic and clinical characteristics of the patients and controls are presented in Table 1 . (Kurtzke 1983) , and disease severity with the Multiple Sclerosis Severity Score (MSSS) (Roxburgh et al. 2005) . The MRI scans of the brain and cervical column were performed with 1.5 or 3.0 Tesla machines, using a 3 mm slice thickness. A standard protocol for MS was applied with T1-and T2-weighted sequences, FLAIR, and T1 following a standard dose of intravenous gadolinium (Gd) contrast. Because Gdenhancement on MRI appears in the majority of cases during a period of 6 weeks, mean 3.07 weeks (Cotton et al. 2003) , we choose to include only MRI performed 6 weeks before or after lumbar puncture in order to evaluate correlation between MRI measures and CSF biomarker concentrations. New disease activity on MRI compared to a previous MRI was defined as a new Gdenhanced lesion or new or enlarged T2 lesion.
Blood tests and CSF sampling
Peripheral blood and CSF were sampled at the clinical assessment. The CSF samples were handled according to the consensus protocol of the BioMS-EU network for CSF biomarker research in MS (Teunissen et al. 2009 ). Increased concentrations of NFL in CSF were expected from relapse onset and approximately 100 days thereafter (Lycke et al. 1998) . In line with this observation, we considered CSF to be obtained during relapse if lumbar puncture was performed within this period of time.
Biomarker analysis
All analyses were performed by board-certified laboratory technicians at the Clinical Neurochemistry Laboratory of Sahlgrenska University Hospital according to protocols approved by the Swedish Board for Accreditation and Conformity Assessment. CSF NFL levels were measured, using a sensitive sandwich ELISA method (NF-light â ELISA kit; UmanDiagnostics AB, Ume a, Sweden). The intra-and inter-assay coefficients of variation were < 10%. The lower limit of quantification (LLoQ) of the assay was 31 pg/mL. GFAP was measured in the CSF by ELISA as previously described in detail (Rosengren et al. 1994) . The LLoQ of the GFAP assay was 16 pg/mL. CSF CXCL13 levels were measured by ELISA (Human CXCL13/BLC/BCA-1 Immunoassay; R&D Systems Inc., Abingdon, UK) according to the manufacturer's instructions. The average intra-and inter-assay coefficients of variation were ≤ 10% and the LLoQ was 7.8 pg/mL. CHI3L1 in the CSF was analyzed with solid phase sandwich ELISA (Human Chitinase 3-like 1 Quantikine ELISA Kit; R&D Systems Inc., Minneapolis, MN, USA). The intraassay coefficient of variation was < 7% and the LLoQ was 8.15 pg/ mL. CSF CCL2 levels were also analyzed by solid phase sandwich ELISA (Human CCL2/monocyte chemoattractant protein-1 Quantikine ELISA Kit; R&D Systems Inc., Minneapolis, MN, USA). The intra-and inter-assay coefficients of variation were ≤ 8% and the LLoQ was 10 pg/mL. CSF levels of NGRN were measured using an in-house ELISA with the monoclonal antibody Ng7 (BioLegend, San Diego, CA, USA) as the capture antibody and the rabbit anti-NGRN antibody (Upstate, Billerica, MA, USA) as the detecting antibody as described previously (Kvartsberg et al. 2015) . The LLoQ was 125 pg/mL and the mean intra-assay coefficient of variation 17%. Chitotriosidase activities in the CSF were measured by an in-house method as described previously (Novakova et al. 2016) . The LLoQ was 0.2 nkat/L and intra-and inter-assay coefficients of variation < 10%. CSF samples below the LLoQ were designated as having the value of the LLoQ.
Statistical analysis
Visual inspection of the data and Shapiro-Wilk test of normality did not show a normal distribution of the biomarkers; therefore, nonparametric tests were used in this study. 
Results
The influence of DMTs on biomarker concentrations RRMS patients had significantly higher mean CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 than controls (p < 0.001), but the mean CSF levels of GFAP, CCL2, and NRGN did not significantly differ between patients and controls (Table 2 ). Excluding patients with relapse (n = 15), the mean CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 were still higher than in controls (p = 0.002, p < 0.001, p = 0.005, and p < 0.001, respectively). The CSF levels of NFL, CXCL13, CHI3L1, and CHIT1 were also significantly higher in untreated patients and in patients treated with interferon beta compared to controls (p < 0.001). In patients treated with natalizumab, only CHI3L1 and CHIT1 were significantly elevated in the CSF compared to controls (p = 0.001 and p = 0.009, respectively).
Patients treated with interferon beta had significantly higher levels of NFL (p = 0.008), CXCL13 (p = 0.001), and CHIT1 (p = 0.026) than those treated with natalizumab (Figs 1-4) . We found no significant difference in the levels of GFAP, CHI3L1, NGRN, or CCL2 between patients treated with interferon beta and natalizumab (Table 2) .
Clinical and radiological characteristics of patients
Patients without treatment or on first-line treatment had more disease activity than those on second-line treatment based on both clinical and radiological measures (Table 3) . Within 100 days (mean 51, range 4-98 days) prior to lumbar puncture, 15 patients without treatment or on interferon beta treatment had relapse, and 17 patients had ≥ 1 Gd-enhanced lesion, whereas no patient on natalizumab treatment had relapse and only one of them had one Gd-enhanced lesion.
The median EDSS and MSSS in the group without treatment, on interferon beta and on natalizumab was 1.5 (range 0-5.0) and 2.44 (0.67-9.18), 2.0 (range 0-6.5) and 3.05 (range 0.17-9.09), and 3.5 (range 0-7.5) and 3.46 (range 0.10-9.13), respectively. We found no significant group difference regarding EDSS and MSSS. The mean age was lower in patients on interferon beta (36 years, range 19-55 years) compared to patients on natalizumab (42 years, range 23-59 years, p = 0.017), and the disease duration was shorter in patients on interferon beta (6 years, range 1-15 years) compared to patients on natalizumab (13 years, range 4-23 years, p < 0.001).
Relationships between biomarker concentrations and clinical and radiological disease activity The CSF levels of NFL, CHI3L1, and CHIT1 were higher in patients with a clinical relapse (n = 15) than patients in clinical remission (p = 0.002, p = 0.006, and p = 0.006, respectively). MRI was performed within an average of 23 days (range 1-42 days) before or after lumbar puncture (n = 25) and compared to a previous MRI performed on average 578 days (range 81-1294 days) ago. The CSF levels of both NFL and CXCL13 were higher in patients with new T2 lesions (n = 16) than patients without new T2 lesions (n = 9, p = 0.007 and p = 0.014, respectively). When only selecting patients with ≥ 1 Gd-enhanced lesion (n = 7), the levels of CXCL13 and NGRN were higher and the levels of CCL2 were lower than in patients without Gd-enhanced lesions (n = 18, p = 0.003, p = 0.049 and p = 0.029, respectively). Note that no differences were observed in NGRN concentrations between patients and controls or between first-and second-line treatments. NFL, CHI3L1, and CHIT1 levels correlated with the clinical relapse rate (r = 0.414, p = 0.001; r = 0.358, p = 0.0015; and r = 0.359, p = 0.005, respectively). The level of CHI3L1 was related to disability and disease severity based on the EDSS and MSSS, respectively (r = 0.274, p = 0.036 and r = 0.297, p = 0.022). CXCL13 and CCL2 
Biomarker concentrations in patients and healthy controls
The levels of NFL, GFAP, CHI3L1, and CCL2 were detectable in all patients and controls. The levels of CXCL13 were below the LLoQ in 39 controls and 38 patients, the levels of CHIT1 were below the LLoQ in 13 controls and 5 patients, and the levels of NGRN were below the LLoQ in 14 controls and 21 patients. The mean concentrations of CSF biomarkers in healthy controls are presented in Table 2 . The NFL, GFAP, CHI3L1, and CCL2 levels were agedependent; therefore, all of the correlation analyses were adjusted for age. We found no influence of gender on the analyzed biomarkers. The disease duration did not show any influence on the biomarker concentrations in this patient group. Except for a significant relationship between GFAP and CHI3L1 (r = 0.552, p < 0.001), no correlations were found between the analyzed biomarkers in healthy controls. We found correlations between biomarkers of inflammation and degeneration in patients (Table 4) ; GFAP correlated with CHI3L1 (r = 0.352, p = 0.007), NFL correlated with CHI3L1 (r = 0.330, p = 0.011), and NFL correlated CHIT1 (r = 0.298, p = 0.023). CHIT1 correlated with two other inflammatory biomarkers, CHI3L1 and CXCL13 (r = 0.499, p < 0.001 and r = 0.298, p = 0.023, respectively).
The mean CSF cell count (mononuclear cells) was 5.43 9 10 6 /L (range 0-16) in patients without treatment, 5.67 9 10 6 /L (range 0-34) in patients on interferon beta and 0.53 9 10 6 /L (range 0-2) in patients on natalizumab treatment. The CSF cell count highly correlated with the inflammatory biomarker CXCL13 (r = 0.670, p < 0.001), whereas the correlations between CSF cell count and NFL (r = 0.294, p = 0.024) and CCL2 (r = À0.341, p = 0.008) were lower.
Discussion
The influence of DMTs on the concentrations of seven CSF biomarkers that reflect different aspects of the immunopathogenesis of RRMS was explored in this study. We show that B-cell regulation (CXCL13), microglial activation (CHIT1, CHI3L1), and axonal damage (NFL) are all associated with disease activity in RRMS. Higher levels of these CSF biomarkers were observed in patients treated with interferon beta compared to those treated with natalizumab, suggesting that the efficacy of therapeutic intervention can be monitored by these biomarkers.
In previous studies, CSF levels of NFL and CXCL13 were shown to be associated with disease activity (Malmestrom et al. 2003; Khademi et al. 2011) . Thus, NFL and CXCL13 were increased during relapse (Malmestrom et al. 2003; Khademi et al. 2011) and in the presence of contrast enhancing lesions on MRI . In this study, we confirmed the association between NFL and CXCL13 and ongoing clinical and MRI activity, but we also showed that these biomarkers correlate with new or enlarged T2 lesions in clinically stable patients. Thus, even new or enlarging lesions that do not disrupt the blood-brain barrier influence the rate of axonal damage. We did not have access to spinal cord MRI scans and cannot exclude the possibility that occasional patients could have had enhancing cord lesions. However, clinically silent enhancing cord lesions are rare and likely do not account for this finding at an aggregate level.
Glial activation occurs during inflammation or damage of the CNS (Eng and Ghirnikar 1994; Bonneh-Barkay et al. 2012) . In previous studies, increased levels of CHI3L1, CHIT1, and GFAP were associated with disease activity (Olsson et al. 2012; Malmestrom et al. 2014) or disease progression (Comabella et al. 2010; Axelsson et al. 2011 ; et al. 2013; Martinez et al. 2015; Burman et al. 2016) . Although CHI3L1 correlated with GFAP, only CHI3L1 correlated with clinical measures of progression (i.e., EDSS) and disease severity (i.e., MSSS). However, in previous studies, the correlation between GFAP and EDSS or MSSS (Malmestrom et al. 2003; Axelsson et al. 2011) was limited to patients with progressive MS or associated with earlier neurological deterioration and EDSS progression (Martinez et al. 2015) . Thus, the selection of RRMS patients and the cross-sectional approach in this study probably influenced the results.
Modvig
In contrast to previous studies on MCI and AD (Thorsell et al. 2010; Kester et al. 2015; Portelius et al. 2015) , NGRN levels were normal in our patients with RRMS. The NGRN level increases as the dendritic spines degenerate and is associated with cognitive decline and the intensity of synaptic and neuronal degeneration in MCI and AD (Portelius et al. 2015) . Although axonal damage may become extensive in RRMS, we did not find signs of dendritic spine involvement in our patients.
In this study, we confirmed that natalizumab-treated patients have CSF NFL and CXCL13 levels similar to those of healthy controls as previously reported [2, 18] , whereas the CSF concentration of CHI3L1 and CHIT1 (Olsson et al. 2012) do not reach normal levels. Thus, a low grade microglial activation seemed to be present even in natalizumab-treated RRMS patients who were clinically and radiologically stable. In RRMS patients, DMTs decreased CSF concentrations of NFL, CXCL13, CHIT1, and CHI3L1, whereas GFAP, NGRN, and CCL2 were unaffected. However, because the CSF concentrations of CXCL13 and CHIT1 were frequently below the detection levels of the immunoassay, their usefulness for monitoring therapeutic efficacy seemed limited.
In order to correctly interpret CSF biomarker data in relation to disease activity or treatment efficacy, certain aspects must be considered. Firstly, the treatment duration may influence biomarker levels. Both first-and second-line MS therapies usually achieve an effect on MRI and clinical measures after several months of treatment. However, none of our patients were on DMTs for less than 1 year. Secondly, some of the biomarkers are age-dependent e.g. NFL (Lycke et al. 1998; Malmestrom et al. 2003; Modvig et al. 2013) , GFAP (Rosengren et al. 1994; Malmestrom et al. 2003) , CHI3L1 (Modvig et al. 2013) , and CCL2 (Conductier et al. 2010) ). In this study, all correlations were adjusted for age. Moreover, in the subgroup analysis based on treatment, the group treated with natalizumab was older. However, the expected influence of age seemed limited, as significantly lower biomarker levels were found in this subgroup. Thirdly, repeated lumbar puncture may not be feasible in some patients because of side effects or a fear of the sampling procedure. Therefore, the possibility of clinically monitoring therapeutic interventions using CSF Table 4 Relationships between biomarkers of inflammation and degeneration NFL, neurofilament light protein; GFAP, glial fibrillary acidic protein; CXCL13, C-X-C motif ligand 13; CHI3L1, chitinase-3-like protein 1; NGRN, neurogranin; CHIT1, chitotriosidase; CCL2, C-C motif chemokine ligand 2.
biomarkers is limited. Results from analyses of CSF biomarkers may essentially contribute to the evaluation of new DMTs in phase II trials or in difficult therapeutic decisions for selected patients. However, NFL and CXCL13 have been reported to be measures of the disease activity of MS in serum (Festa et al. 2009; Kuhle et al. 2015b) . Thus, the evolution of extremely sensitive assays may make it possible to replace CSF with serum or plasma, even for CNSspecific antigens or inflammatory disorders of the CNS. Further studies of biomarkers obtained from peripheral blood are highly warranted in MS to establish them as biomarkers of disease progression, disease activity, and treatment efficacy.
In conclusion, this study showed that CSF biomarkers related to different pathological processes involved in MS reflect both disease activity and DMT efficacy. The association between neurodegenerative and inflammatory biomarkers confirms the hypothesis regarding inflammatory-induced degeneration, at least in the relapsing-remitting phase of the disease (Owens 2003; Stadelmann et al. 2011) . The determination of CSF NFL and CHI3L1 levels may be useful for measuring treatment efficacy in clinical trials and can also be used to monitor DMTs in clinical practice to provide an additional dimension in the assessment of treatment efficacy.
